‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ( BMD ) Data Reported in Phase 2 EB613 Clinical Trial ‒ ‒ Company Expect s to Report Bio m arker

BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S.

‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21   with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to Inform the Design of Potential Global Phase 3 Clinical Trial ‒ BOSTON and JERUSALEM, Israel, Nov.

BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C.

BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference

‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on  Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner – ‒ Company Expects to Complete Patient Enrollment in Q3:20 and Report Interim  Biomarker Data from 2.5 mg Dose in Q1:21 with Final Data Expected in Q2:21

BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S.

BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of Directors has appointed Roger Garceau as Interim Chief Executive Officer, effective immediately.

BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10,

‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒ ‒ Oral PTH Described by Clinicians as Potential Game-Changer that Addresses Substantial Unmet Need with Possibility of Improving Patient Compliance and Comfort ‒